165 results about "Immunoadsorption" patented technology

The invention belongs to the field of immunological detection, and provides a double-antibody sandwich ELISA kit for detecting the content of human beta-NGF. The enzyme-linked immunosorbent assay kit constructed by the invention is based on a double-antibody sandwich method, and is combined with a biotin-streptavidin signal amplification system and an enzyme developing amplification system, so that the detection sensitivity and specificity are greatly improved, and low-content samples can be accurately and quickly detected. The kit shows excellent stability and specificity and can be used for quantitatively detecting the content of beta-NGF in samples such as human serum, cell supernatant or tissue homogenate, so that an objective detection basis is provided for diagnosis, curative effect evaluation and pathogenesis research of related diseases.

The invention discloses a variable region amino acid sequence of a monoclonal antibody of a West Nile virus non-structural protein NS1 and application of the variable region amino acid sequence, and belongs to the technical field of medicines. According to the invention, West Nile virus non-structural protein NS1 expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the West Nile virus non-structural protein NS1 are screened from rabbit spleen cells through flow sorting, and a signal peptide and a variable region gene fragment of an antibody are cloned through reverse transcription-polymerase chain reaction; according to the present invention, the non-structural protein NS1 of flaviviridae flaviviridae virus is taken as a template, and is connected with a constant region gene to an expression vector, and after mammalian cell expression and purification, the monoclonal antibody which has high affinity and is not combined with the non-structural protein NS1 of other eight viruses of flaviviridae flaviviridae virus is obtained through enzyme-linked immunosorbent assay; the monoclonal antibody has application value in diagnosis and prevention and treatment of West Nile virus infection.

The invention discloses a high-affinity monoclonal antibody for recognizing group B streptococcus SIP (Session Initiation Protocol) protein or an antigen binding fragment thereof. The amino acid sequence of a heavy chain variable region of the antibody is as shown in SEQ ID NO.1, and the amino acid sequence of a light chain variable region of the antibody is as shown in SEQ ID NO.5. The lowest detection limit of the group B streptococcus SIP protein double-antibody sandwich enzyme-linked immunosorbent assay established by taking the monoclonal antibody or the antigen binding fragment thereof as a capture antibody on the SIP protein is 0.32 ng / mL. The lowest detection limit of a group B streptococcus SIP protein double-antibody sandwich fluorescence immunochromatography assay method established by taking the monoclonal antibody or the antigen binding fragment thereof as a capture antibody on SIP protein is 0.08 ng / mL, and the lowest detection limit on GBS bacterial liquid reaches 1 * 10 < 3 > CFU / mL, which is obviously higher than the lowest detection limit of the existing detection reagent and literature report; the method can be used for qualitative and quantitative detection of the group B streptococcus SIP protein.

1. The name of the design product: Fully automatic enzyme-linked immunosorbent assay workstation. 2. The use of the design product: For enzyme-linked immunosorbent assay or detection. 3. The design key points of the design product: Lies in the shape. 4. The picture or photo that best shows the design key points: Perspective view.

The invention discloses a paralichthys olivaceus rhabdovirus G protein tandem antigen epitope peptide and application thereof, and belongs to the field of fish molecular immunology. The amino acid sequence of the tandem antigen epitope peptide is shown as SEQ ID NO: 1. The preparation method comprises the following steps: (1) firstly, analyzing structural characteristics of HIRRV-G protein, predicting B cell antigen epitopes of the HIRRV-G protein, screening the antigen epitopes with advantages on the basis of a prediction result, and synthesizing the antigen epitopes; (2) screening a candidate peptide fragment with high affinity through an enzyme-linked immunosorbent assay; and (3) sequentially connecting the high-affinity peptide fragment sequences meeting the requirements by using a GPGPG connexon, cloning the connected sequences into a pET-28a prokaryotic expression vector, and performing induced expression to obtain the tandem antigen epitope peptide. Compared with a full-length G protein, the tandem antigen epitope peptide is smaller in molecular weight, higher in stability and higher in hydrophilicity; a large number of specific antibodies can be induced in fish bodies, and the death rate of the paralichthys olivaceus infected by viruses is remarkably reduced. The method can be used for HIRRV diagnosis detection reagent and subunit vaccine development.

The invention discloses a detection method based on combination of anti-NF155 antibody detection and enzyme-linked immunosorbent assay. According to the detection method, an analysis model based on an XGBoost model algorithm is established by adopting anti-NF155 antibody detection of a patient and detection data of an enzyme-linked immunosorbent assay in combination with autologous clinical data of the patient, so that CIDP subtype classification is performed on the patient, and personalized treatment scheme suggestions are provided in combination with illness state dynamic data of the patient. Meanwhile, the invention provides a corresponding detection system which comprises a laboratory, a data storage library and an analysis unit, the anti-NF155 antibody detection is executed through laboratory equipment, and detection data and patient autologous clinical data are stored in the data storage library. The analysis unit establishes an analysis model based on an XGBoost model algorithm based on a machine learning algorithm.

The invention provides a human metapneumovirus monoclonal antibody and application thereof, and belongs to the technical field of immunity. The monoclonal antibody F720-1 provided by the invention only has binding activity to conformation F protein before human metapneumovirus fusion, and the monoclonal antibody F390-6 has binding activity to conformation F protein before human metapneumovirus fusion and conformation F protein after human metapneumovirus fusion. Through pairing, it is determined that F720-1 and F390-6 can conduct proportion detection on Pre-F and Post-F in the human metapneumovirus F protein through an enzyme-linked immunosorbent assay double-antibody sandwich method and conduct quantification on Pre-F. The double-antibody sandwich ELISA method has a good linear relation and detection limit when used for detecting the proportion of the Pre-F protein to the Post-F protein in the F protein. The method is expected to be used for accurate evaluation in human metapneumovirus protein experimental vaccine stock solution and vaccine verification.

The invention discloses application of hydrogen-rich water in preparation of a drug for treating Duchenne type muscular dystrophy, and particularly relates to the technical field of medicines.The random control experiment is adopted, homologous c57 mice serve as a normal control group, mdx mice are randomly divided into a model group and a hydrogen-rich water group, and the exercise ability is evaluated through a four-limb holding power test and a rotating bar test; detecting mouse creatine kinase by an enzyme-linked immunosorbent assay; carrying out hematoxylin-eosin, NADH-tetrazole reductase and improved Goori three-color dyeing, and carrying out cytochrome C oxidase, succinate dehydrogenase and SDH-COX combined dyeing to observe the pathological change of the skeletal muscle tissue; the invention discloses that the muscle injury condition of a Duchenne type muscular dystrophy model mouse is improved by the hydrogen-rich water through a mitochondrial protection mechanism, and the hydrogen-rich water has a relatively high application prospect and a relatively high economic value.

The invention discloses an anti-phenacetin monoclonal antibody hybridoma cell strain AD, a preparation method and application thereof, and relates to the technical field of food safety immunodetection. The monoclonal antibody hybridoma cell strain is named monoclonal cell strain AD and the number CGMCC19681. The Phe-BA obtained by the hydrolysis of the reaction product of the phenacetin metabolite acetaminophen and ethyl 4-bromobutyrate is used as the hapten, and the hapten is coupled with the carrier protein to prepare the immunogen Phe-BA-BSA. After the mice were immunized with the immunogen Phe-BA-BSA, they were fused with myeloma cells by PEG method, screened by indirect competitive enzyme-linked immunosorbent assay and subcloned five times to obtain hybridoma cell lines. The monoclonal antibody secreted by the cell line can be made into a phenacetin detection kit, which has good affinity and detection sensitivity for phenacetin, and can be used for immunodetection of phenacetin residues in food.

The application discloses a tandem antigen epitope peptide of G protein of Paralichthys olivaceus rhabdovirus and application thereof, and belongs to the field of fish molecular immunology. The amino acid sequence of the tandem antigen epitope peptide is shown as SEQ ID NO:1. The preparation method of the application comprises the following steps: (1) first, analyzing the structural characteristics of HIRRV-G protein and predicting B cell antigen epitopes, and synthesizing the antigen epitopes with advantages based on the prediction results; (2) then, screening candidate peptide segments with high affinity through enzyme-linked immunosorbent assay; (3) sequentially connecting the high-affinity peptide segment sequences meeting the requirements by using a GPGPG linker, and cloning the connected sequences into a pET-28a prokaryotic expression vector, so that the tandem antigen epitope peptide is obtained after induced expression. Compared with the full-length G protein, the tandem antigen epitope peptide has smaller molecular weight, stronger stability and stronger hydrophilicity; the tandem antigen epitope peptide can induce a large amount of specific antibodies in fish bodies, and significantly reduces the mortality of fish infected by the virus. The tandem antigen epitope peptide can be used for the development of HIRRV diagnostic reagents and subunit vaccines.

Described herein are methods and kits for the detection of platelet-activating pathogenic antibodies in samples from patients suspected of having platelet-activating antibodies or non-HIT anti-PF4 antibody mediated syndromes using platelets and polyvinyl sulfonate or salts thereof. Upon platelet activation, thrombospondin-1 (TSP1), a platelet granule protein, is released and can be detected using a TSP1 antigen capture enzyme linked immunosorbent assay (ELISA) to accurately measure platelet activation.

The application discloses nanobodies against E protein of chikungunya virus and application in virus detection, and the nanobodies against E protein of chikungunya virus include N055 and 10G4 antibodies, and both have high affinity and binding activity with antigens. A double antibody sandwich enzyme-linked immunosorbent assay method constructed by the nanobodies of the N055 and 10G4 antibodies can efficiently detect E protein of chikungunya virus and virus-like particles, and the detection sensitivity can reach 49 pg / mL, and the antibody combination has wide application prospects in diagnosis and pathogen detection of chikungunya virus disease.

The invention discloses a chikungunya virus envelope E2 protein monoclonal antibody and application thereof, and belongs to the technical field of medicines. The chikungunya virus envelope protein E2 expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the chikungunya virus envelope protein E2 are screened from rabbit spleen cells through flow sorting, and signal peptide and variable region gene fragments of an antibody are cloned through reverse transcription-polymerase chain reaction. According to the present invention, the chikungunya virus-resistant monoclonal antibody with high neutralizing activity and capable of 100% protection of mice against chikungunya virus lethal attack is obtained by carrying out enzyme-linked immunosorbent assay, in-vitro virus neutralization and mouse toxicity attack experiment after mammalian cell expression and purification, and the recombinant chikungunya virus-resistant monoclonal antibody has characteristics of high neutralizing activity and high immunogenicity, and can be used for preparing the chikungunya virus-resistant monoclonal antibody, and the recombinant chikungunya virus-resistant monoclonal antibody. The monoclonal antibody has application value in prevention and treatment of yellow fever.

In accordance with at least one aspect of this disclosure, a method for preparing a patient for a diagnostic procedure and / or for receiving a therapy using a disease targeted drug is provided. The method can include the steps of a) identifying one or more soluble targets detectable in plasma of the patient; and b) extracorporeally removing the soluble targets from the plasma of the patient. Extracorporeally removing the soluble targets from the plasma of the patient can include using plasmapheresis or immunoadsorption to prepare a patient for a procedure using disease targeted treatment or diagnostics. Additionally, or alternatively, dose modulation can be used to proportionally increase the concertation of the diagnostic / treatment agent relative to the concentration of the soluble target in the blood, improving the outcome treatment and diagnostic procedures over conventional methods.

A method for detecting hepatitis B virus comprising a step of bringing a sample into contact with an antibody which binds to a surface antigen protein of hepatitis B virus, and a lectin. The surface antigen protein of hepatitis B virus may be an S protein, and the lectin may be wheat germ agglutinin. The detection method may involve an ELISA measurement and may be used for testing, prophylaxis, or planning treatment of hepatitis B virus, and for screening medicines.

The invention provides a method for detecting new antibiotic pollutants in a water body sample by combining solid-phase extraction and enzyme-linked immunosorbent assay, which comprises the following steps: (a) selecting an organic solvent, so that R2 of a standard curve obtained by enzyme-linked immunosorbent assay of a standard substance containing the new antibiotic pollutants and an aqueous solution of the organic solvent is greater than 0.98; (b) determining the optimal concentration of the organic solvent by taking the quantitative detection interval, the sensitivity, the detection limit and the precision of enzyme-linked immunosorbent assay as evaluation indexes and combining a CRITIC weight method; and (c) preparing the new antibiotic pollutants enriched by the organic solvent selected in the step (a) through solid-phase extraction of the water body sample and water into a redissolved aqueous solution, and detecting the redissolved aqueous solution through enzyme-linked immunosorbent assay to determine the concentration of the new antibiotic pollutants in the water body sample, wherein the concentration of the organic solvent in the redissolved aqueous solution is the optimal concentration. The invention also provides a method for optimizing enzyme-linked immunosorbent assay.

The invention relates to an anti-mouse IgG nano antibody and alkaline phosphatase fusion protein as well as a preparation method and application thereof. The anti-mouse IgG nano antibody and alkaline phosphatase fusion protein sequentially comprises an anti-mouse IgG nano antibody, a connecting peptide and shewanella alkaline phosphatase from an amino terminal to a carboxyl terminal. The fusion expression of the anti-mouse IgG nano antibody and shewanella alkaline phosphatase in escherichia coli is designed, so that various defects of a chemical labeling method can be avoided, a high-purity and high-specific activity enzyme-labeled antibody can be prepared, the preparation period of a second antibody can be shortened, the preparation process of the second antibody can be simplified, the stability of batches can be improved, and the dependence on experimental animals can be reduced. The prepared anti-mouse IgG nano antibody and alkaline phosphatase fusion protein can be applied to the field of immunodetection, such as a chemiluminescence immunoassay method, an enzyme-linked immunosorbent assay method, an enzymatic fluorescence immunoassay method, an immunoblotting method and the like.

The invention discloses a method for detecting mosquito salivary protein specific immune globulin E in animal serum through a capture method enzyme-linked immunosorbent assay, and belongs to the technical field of immunodetection. The monoclonal antibody specifically combined with the human or mouse IgE Fc fragment is used as the capture antibody, and the V5 tag is combined, so that the interference of IgG in a detection sample can be avoided, and the detection sensitivity breaks through the limit of an existing detection mode.

The invention discloses a yellow fever virus envelope protein monoclonal antibody and application thereof, and belongs to the technical field of medicines. Yellow fever virus envelope protein E expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the yellow fever virus envelope protein E are screened from rabbit spleen cells through flow sorting, and signal peptide and variable region gene fragments of an antibody are cloned through reverse transcription-polymerase chain reaction. According to the present invention, the monoclonal antibody with high neutralizing activity and capable of completely protecting mice from yellow fever virus lethal attack is obtained by using the monoclonal antibody as a template, connecting the monoclonal antibody and the constant region gene to an expression vector, carrying out mammalian cell expression and purification, and carrying out enzyme-linked immunosorbent assay, in-vitro virus neutralization and mouse virus attack experiment, such that the monoclonal antibody has high neutralizing activity and can completely protect mice from yellow fever virus lethal attack; the monoclonal antibody has application value in prevention and treatment of yellow fever.

The invention relates to the field of biological medicines, and discloses application of serum EPSTI1 in preparation of a product for diagnosing liver cancer and evaluating whether a liver cancer patient is resistant to a revatinib or not. The invention provides a detection means which is convenient and rapid in sampling, small in risk and relatively low in cost, the content of EPSTI1 in serum is detected through an enzyme-linked immunosorbent assay, a liver cancer patient and a non-liver cancer patient can be effectively distinguished, and a lovatinib drug-resistant liver cancer patient and a non-drug-resistant liver cancer patient can be effectively distinguished. Prognosis analysis shows that the serum EPSTI1 can be used as a marker for evaluating the prognosis state of the liver cancer patient taking the lenvatinib, and has important significance in improving the survival rate of the liver cancer patient.

A biomarker for systemic sclerosis, and a detection method therefor and the use thereof. The biomarker is an anti-PRMT5 antibody. The use of PRMT5 in the preparation of a drug or agent for detecting or treating systemic sclerosis, wherein patients with systemic sclerosis are distinguished from healthy controls and patients with other autoimmune diseases by means of detecting the anti-PRMT5 antibody level. The anti-PRMT5 antibody levels in patients with systemic sclerosis are closely correlated with the outcome of skin and pulmonary fibrosis in the patients, and the biomarker has potential value in prognosis evaluation. The detection method using enzyme-linked immunosorbent assay is simple, easy to perform, convenient for translation, and suitable for wide promotion in primary hospitals.

The invention belongs to the field of biology, and particularly relates to a chemiluminescence kit for detecting CEACAM1, a use method and application, the chemiluminescence kit comprises a streptavidin magnetic particle working solution, a biotinylated carcino-embryonic antigen related cell adhesion molecule 1 capture antibody solution and an acridinium ester labeled carcino-embryonic antigen related cell adhesion molecule 1 detection antibody solution. Coupling of acridinium ester and the antibody is efficient and simple, repeatability is good, large-scale production and application are easy, a biotin-avidin amplification system (BAS system) is used in a reaction system, quantitative detection of ultramicro markers is more sensitive and more efficient, and compared with a traditional enzyme-linked immunosorbent assay method, the method has the advantages that the detection sensitivity is high, and the sensitivity is high. The magnetic particle chemiluminescence reagent disclosed by the invention has the advantages of low cost, stable and reliable result, high test flux, convenience in production, small batch difference, easiness in large-scale application and the like.

This invention relates to the field of biological testing and discloses a plasma polypeptide marker, COL1A2, associated with tumor bone metastasis and pain, and its applications. To address the difficulties in early diagnosis of bone cancer pain and tumor bone metastasis, this study examined circulating COL1A2 levels in plasma and found that it was significantly upregulated in patients with bone metastasis and pain, and correlated significantly with clinical pain scores and tumor stage. Using enzyme-linked immunosorbent assay (ELISA) technology, a sensitive and specific COL1A2 detection method was established, capable of identifying the occurrence and stage of bone cancer pain and tumor bone metastasis with high predictive efficacy of 0.95 and 0.94, respectively. This assay is low-cost and simple to operate, making it suitable for clinical application. It provides scientific basis and technical support for screening high-risk populations, early diagnosis of bone metastasis, pain staging, and personalized treatment. This invention is of great significance for optimizing diagnostic and treatment strategies for patients with bone cancer pain and improving clinical translation efficiency.

A homogeneous method for detecting the nucleocapsid protein of the new coronavirus based on a nano-antibody-monoclonal antibody sandwich relates to the field of antigen detection. The present invention prepares a variety of novel coronavirus nucleocapsid protein nano-antibodies as solid-phase antibodies, nucleocapsid protein monoclonal antibodies as detection antibodies, and novel coronavirus N protein as detection targets. A group of antibody pairs with excellent detection performance are screened out by enzyme-linked immunosorbent assay, with a minimum detection line of 0.8 ng / mL. In addition, a one-step activation method couples nano-antibodies and monoclonal antibodies to the surfaces of quantum dot microspheres and magnetic nano-microspheres, respectively, and successfully prepares two probes targeting the nucleocapsid protein of the new coronavirus. It also constructs a magnetic separation immunohomogeneous method for rapid detection of the nucleocapsid protein of the new coronavirus, with a minimum detection line of 0.15 ng / mL. The present invention is simple to operate, low in cost, fast in reaction speed, can realize in situ detection, and has high efficiency in paired antibody screening. It has good application prospects in the rapid detection of novel coronaviruses.

The application discloses a nano antibody against Ebola virus VP40 protein and application thereof in Ebola virus detection, wherein the nano antibody against Ebola virus VP40 protein is a 3E07 antibody. The nano antibody against Ebola virus VP40 protein prepared by the application has the characteristics of high sensitivity and wide binding spectrum. A double antibody sandwich enzyme-linked immunosorbent assay method constructed by 3E07 and 3F06 antibodies can efficiently detect VP40 proteins and virus-like particles of various Ebola virus subtypes such as Zaire, Sudan and Beni, wherein the detection sensitivity of the Ebola virus VP40 protein of Zaire type can reach 0.039 ng / mL, and the antibody combination has a wide application prospect in the diagnosis and pathogen detection of Ebola virus disease.

The invention relates to an anti-ovarian antibody chemiluminiscence kit and a preparation method thereof. The kit comprises amino magnetic beads coated with anti-ovarian antibody recombinant protein, anti-human immune globulin labeled by alkaline phosphatase, an anti-ovarian antibody calibrator and a chemiluminiscence substrate. The method has the beneficial effects that the 7-day acceleration stability of the AOAb coated amino magnetic bead is improved to 95% or above, the signal-to-noise ratio is high, the correlation coefficient is greater than 0.999, the test repeatability CV is less than 3.5%, the reagent correlation and the magnetic bead stability can be better improved, and the test result is ensured to be accurate. By optimizing the amino magnetic bead cross-linking agent, 60 clinical samples are tested and compared with the result of a comparison manufacturer, the total coincidence rate is as high as 98%, and false positive can be effectively reduced. Meanwhile, a detection system is formed by matching with a Guilin superior chemiluminescence immunoassay analyzer IA-260, the testing amount per hour reaches 130 tests, and compared with a traditional colloidal gold immunochromatography method and a traditional enzyme-linked immunosorbent assay method, the detection speed is greatly increased, and the result optimization accuracy is greatly improved.

The invention relates to a nano antibody for specifically recognizing a tacrolimus-antibody compound and application of the nano antibody, and belongs to the technical field of biological detection. A variable region of the nano antibody has three complementary determining regions CDR1, CDR2 and CDR3, can specifically recognize a tacrolimus-antibody compound, and can be used for detecting drugs by a double-antibody sandwich method; the kit is widely suitable for various immunodetection technologies such as an enzyme-linked immunosorbent assay (ELISA), a chemiluminescence immunoassay (CLIA), an electrochemical luminescence immunoassay (ECLIA), a fluorescence immunoassay (FIA), an immunochromatography test strip method and the like. According to the method, the limitation of a traditional competition method is overcome, high-sensitivity, high-specificity and high-stability detection is realized, the method can be adapted to various detection platforms, and a portable pretreatment process without centrifugation can also be realized.

The invention relates to a Brucella lipopolysaccharide monoclonal antibody and a cELISA detection kit and detection method based on the same, the monoclonal antibody comprises a heavy chain variable region and a light chain variable region, and is characterized in that the amino acid sequence of the heavy chain variable region is SEQ ID No.1, and the corresponding nucleotide sequence is SEQ ID No.2; the amino acid sequence of the light chain variable region is SEQ ID No.3, and the corresponding nucleotide sequence is SEQ ID No.4. The monoclonal antibody is only specifically combined with smooth LPS of brucella, and has no cross reaction with 21 pathogens such as rough brucella, yersinia O: 9 and the like. The sensitivity of a competitive enzyme-linked immunosorbent assay (cELISA) kit developed on the basis of the antibody reaches 1: 25600 and is improved by 200 times compared with that of a traditional method, the detection time is shortened to 90 min, the in-plate / inter-plate variable coefficient is lower than 9.87%, and the antibody is suitable for high-throughput screening of multi-host serum.

The invention belongs to the technical field of biotechnology and protein determination, and particularly relates to confining liquid as well as a preparation method and application thereof. Modified bovine serum albumin and recombinant casein polypeptide are used as core components of the confining liquid, hydroxypropyl-beta-cyclodextrin, polyglycerol fatty acid ester and other auxiliary components are added, and the confining liquid is prepared through a specific technology. The modified bovine serum albumin and the recombinant casein polypeptide have a synergistic effect, so that active sites of the detection carrier can be efficiently sealed; the stabilizing agent and other components are supplemented, so that the stability and compatibility of the confining liquid are improved. The confining liquid is simple and convenient in preparation process, controllable in cost, suitable for various detection carriers such as elisa plates and nitrocellulose membranes, capable of reducing non-specific binding and improving detection sensitivity, and suitable for various biological detection scenes such as enzyme-linked immunosorbent assay.

The invention belongs to the technical field of bioengineering, and particularly relates to a preparation method and application of a calprotectin S100A8 / A9 dimer mouse monoclonal antibody, the monoclonal antibody comprises a heavy chain variable region and a light chain variable region; the heavy chain variable region comprises any one of amino acid sequences as shown in SEQ ID NO.22-24; the heavy chain variable region comprises any one of amino acid sequences as shown in SEQ ID NO.22-24; the light chain variable region comprises an amino acid sequence as shown in SEQ ID NO. 28-30. According to the present invention, the S100A8 / A9 heterodimer protein with biological activity and immunostimulation function is prepared, the protein is used to immunize mice, the specific gene engineering antibody of the S100A8 / A9 heterodimer protein is prepared, the antibody pair with high sensitivity is screened, and the calprotectin S100A8 / A9 double-antibody sandwich enzyme-linked immunosorbent assay method is preliminarily developed;